Literature DB >> 11245471

A possible role of p73 on the modulation of p53 level through MDM2.

X Q Wang1, W M Ongkeko, A W Lau, K M Leung, R Y Poon.   

Abstract

MDM2, one of the transcriptional targets of p53, can target p53 for degradation in a negative feedback loop. The p53-related protein p73, however, can bind to MDM2 but is not consequently down-regulated. Here we demonstrate that p73 could transactivate the MDM2 promoter in p53-null cell lines. In p53-null cell lines, the level of MDM2 was increased by p73 due to increases in transcription and protein stability of MDM2. In transient transfection assays, inhibition of the transcriptional activity of p73 required a higher amount of MDM2 than that of p53. This is probably due to the fact that MDM2 can target p53, but not p73, for degradation. We demonstrated further that the level of p53 could be altered by a cooperation between MDM2 and p73, but not by transcriptional inactive mutants of p73. Expression of p73 resulted in a reduction of the ectopically expressed p53 in transient transfections or of the endogenous p53 induced by Adriamycin- or UV-mediated damage. These reductions of p53 were likely to be due to an increase in MDM2-mediated proteolysis. These results suggest the possibility that different levels of p73 in the cell may act as a mechanism to modulate p53 responses after DNA damage and other stresses and that an increase rather than a decrease in p73 may play a role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245471

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  How many mutant p53 molecules are needed to inactivate a tetramer?

Authors:  Wan Mui Chan; Wai Yi Siu; Anita Lau; Randy Y C Poon
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

2.  Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients.

Authors:  Amira Toumi Arfaoui; Lilia Ben Mahmoud Kriaa; Olfa El Amine El Hadj; Majid A Ben Hmida; Myriam Khiari; T Khalfallah; Lasaad Gharbi; Sabeh Mzabi; Sadaa Bouraoui
Journal:  Virchows Arch       Date:  2010-07-20       Impact factor: 4.064

3.  Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma.

Authors:  Chunying Li; Kexin Chen; Zhensheng Liu; Li-E Wang; Jeffrey E Gershenwald; Jeffrey E Lee; Victor G Prieto; Madeleine Duvic; Elizabeth A Grimm; Qingyi Wei
Journal:  J Invest Dermatol       Date:  2007-11-29       Impact factor: 8.551

4.  Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers.

Authors:  Xingming Chen; Erich M Sturgis; Adel K El-Naggar; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2008-08-13       Impact factor: 4.944

5.  Association of p73 G4C14-to-A4T14 polymorphism with lung cancer risk.

Authors:  Hua Liu; Yuli Liang; Hua Liao; Lanying Li; Hongyun Wang
Journal:  Tumour Biol       Date:  2014-06-19

6.  Tyms double (2R) and triple repeat (3R) confers risk for human oral squamous cell carcinoma.

Authors:  Alexandre Medeiros Bezerra; Thalita Araújo Sant'Ana; Adriana Vieira Gomes; Aurora Karla de Lacerda Vidal; Maria Tereza Cartaxo Muniz
Journal:  Mol Biol Rep       Date:  2014-10-24       Impact factor: 2.316

7.  Combined p53-related genetic variants together with HPV infection increase oral cancer risk.

Authors:  Zhongqiu Wang; Erich M Sturgis; Yang Zhang; Zhigang Huang; Qi Zhou; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

8.  Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Authors:  Eva Tonsing-Carter; Barbara J Bailey; M Reza Saadatzadeh; Jixin Ding; Haiyan Wang; Anthony L Sinn; Kacie M Peterman; Tiaishia K Spragins; Jayne M Silver; Alyssa A Sprouse; Taxiarchis M Georgiadis; T Zachary Gunter; Eric C Long; Robert E Minto; Christophe C Marchal; Christopher N Batuello; Ahmad R Safa; Helmut Hanenberg; Paul R Territo; George E Sandusky; Lindsey D Mayo; Christine M Eischen; Harlan E Shannon; Karen E Pollok
Journal:  Mol Cancer Ther       Date:  2015-10-22       Impact factor: 6.261

9.  Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population.

Authors:  Benyuan Deng; Fei Liu; Yonggang Wei; Limei Luo; Xi Chen; Lvnan Yan; Bo Li
Journal:  Tumour Biol       Date:  2012-10-12

Review 10.  Targeting MDM2 for novel molecular therapy: Beyond oncology.

Authors:  Wei Wang; Jiang-Jiang Qin; Mehrdad Rajaei; Xin Li; Xiaoyi Yu; Courtney Hunt; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2019-10-06       Impact factor: 12.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.